AI-assisted analysis based on the official CRS summary. Source version: Jul 16, 2026. Analysis updated: Sep 20, 2026.
01 — The Text
What.
- The bill reauthorizes through FY2031 NIH grants for research on investigational drugs for ALS in individuals ineligible for clinical trials
- The bill reauthorizes FDA grants for research and development of therapies for ALS and other neurodegenerative diseases
- The bill reauthorizes a Public-Private Partnership involving the FDA and NIH supporting development and regulatory review of neurodegenerative disease treatments
- The bill requires NIH to assess safety and efficacy information when renewing grants and requires grantees to promptly report serious adverse events
- The bill requires the FDA to publish a five-year plan on fostering drug development and investigational drug access for ALS and rare neurodegenerative diseases, and to report on actions taken
02 — The Stakes
So what?
- Research funding for ALS therapies continues through 2031 with explicit reauthorization
- Enhanced oversight mechanisms are established through required safety assessments and adverse event reporting
- The FDA is mandated to develop and publicly report on a coordinated strategy for rare neurodegenerative disease treatments
- Documented effects are limited to what the summary specifies; economic impacts, patient outcomes, or clinical trial enrollment effects are not established in the official summary
03 — The Path
Now what?
- House passed the bill by voice vote on July 22, 2026
- Senate received the bill on July 23, 2026 and placed it on the Legislative Calendar (Calendar No. 466)
- Bill awaits further Senate action; no scheduled vote date is documented
Legislative History
Actions.
- Jul 23, 2026 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026 — Motion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026 — On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026 — Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026 — Considered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026 — At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 20, 2026 — DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026 — Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)